tradingkey.logo
tradingkey.logo
Suchen

PharmaCyte Biotech Inc

PMCB
Zur Watchlist hinzufügen
0.715USD
-0.026-3.51%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
7.68MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über PharmaCyte Biotech Inc Unternehmen

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

PharmaCyte Biotech Inc Informationen

BörsenkürzelPMCB
Name des UnternehmensPharmaCyte Biotech Inc
IPO-datumSep 11, 2003
CEOSilverman (Joshua N)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeSep 11
Addresse3960 Howard Hughes Parkway, Suite 500
StadtLAS VEGAS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl89169
Telefon19175952850
Websitehttps://pharmacyte.com/
BörsenkürzelPMCB
IPO-datumSep 11, 2003
CEOSilverman (Joshua N)

Führungskräfte von PharmaCyte Biotech Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von PharmaCyte Biotech Inc?

Die fünf größten Anteilseigner von PharmaCyte Biotech Inc sind: Mr. Jonathan L. Schechter

Wie viele Institutionen halten Anteile an PharmaCyte Biotech Inc (PMCB)?

Mit Stand vom 2026Q1 halten 67 Institutionen Anteile an PharmaCyte Biotech Inc, mit einem Gesamtmarktwert von etwa 1.07M, was 9.99% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 347985.00 gestiegen.